Addiction-related gene regulation: Risks of exposure to cognitive enhancers vs. other psychostimulants

Progress in Neurobiology

Volumn 100, Issue 1, 2013, Pages 60-80

  Steiner, Heinz ^a   Van Waes, Vincent ^b  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Amphetamine; Cocaine; Cognitive enhancer; Cortex; Dopamine; Gene regulation; Methylphenidate; Psychostimulant; Striatum

Indexed keywords

AMPHETAMINE; CITALOPRAM; COCAINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DYNORPHIN; FLUOXETINE; GLUTAMIC ACID; MESSENGER RNA; METHYLPHENIDATE; MODAFINIL; MONOAMINE; NEUROPEPTIDE; NEUROTENSIN; NEUROTRANSMITTER; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR DELTA FOSB;

ATTENTION DEFICIT DISORDER; BASAL GANGLION; BRAIN MAPPING; COMPARATIVE STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DRUG DEPENDENCE; DRUG EXPOSURE; GENE CONTROL; GENE INDUCTION; HUMAN; IMMEDIATE EARLY GENE; LIMBIC CORTEX; LOW DRUG DOSE; MOTIVATION; NARCOLEPSY; NERVE CELL PLASTICITY; NERVE PROJECTION; NEUROCHEMISTRY; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SUBSTANTIA NIGRA;

ANIMALS; BEHAVIOR, ADDICTIVE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; GENE EXPRESSION REGULATION; HUMANS; NOOTROPIC AGENTS;

EID: 84870926600     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.10.001     Document Type: Review

References (313)

1. Adams D.H., Hanson G.R., Keefe K.A. Differential effects of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique regions of the striatum. Neuroscience 2001, 102:843-851.
2. Adams D.H., Hanson G.R., Keefe K.A. Distinct effects of methamphetamine and cocaine on preprodynorphin messenger RNA in rat striatal patch and matrix. Journal of Neurochemistry 2003, 84:87-93.
3. Adriani W., Leo D., Greco D., Rea M., di Porzio U., Laviola G., Perrone-Capano C. Methylphenidate administration to adolescent rats determines plastic changes in reward-related behavior and striatal gene expression. Neuropsychopharmacology 2006, 31:1946-1956.
4. Adriani W., Leo D., Guarino M., Natoli A., Di Consiglio E., De Angelis G., Traina E., Testai E., Perrone-Capano C., Laviola G. Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual/endocrine parameters in male rats. Annals of the New York Academy of Sciences 2006, 1074:52-73.
5. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends in Neurosciences 1989, 12:366-375.
6. Alburges M.E., Hoonakker A.J., Horner K.A., Fleckenstein A.E., Hanson G.R. Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment. Journal of Neurochemistry 2011, 117:470-478.
7. Alexander G.E., Crutcher M.D., DeLong M.R. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, " prefrontal" and " limbic" functions. Progress in Brain Research 1990, 85:119-146.
8. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience 1986, 9:357-381.
9. Allen J.K., Wilkinson M., Soo E.C., Hui J.P., Chase T.D., Carrey N. Chronic low dose Adderall XR down-regulates cfos expression in infantile and prepubertal rat striatum and cortex. Neuroscience 2010, 169:1901-1912.
10. Andersen S.L. Stimulants and the developing brain. Trends in Pharmacological Sciences 2005, 26:237-243.
11. Andersen S.L., Arvanitogiannis A., Pliakas A.M., LeBlanc C., Carlezon W.A.J. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nature Neuroscience 2002, 5:13-14.
12. Andersson M., Hilbertson A., Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiology of Disease 1999, 6:461-474.
13. Andersson M., Westin J.E., Cenci M.A. Time course of striatal deltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. European Journal of Neuroscience 2003, 17:661-666.
14. Babcock Q., Byrne T. Student perceptions of methylphenidate abuse at a public liberal arts college. Journal of American College Health 2000, 49:143-145.
15. Badiani A., Oates M.M., Day H.E., Watson S.J., Akil H., Robinson T.E. Amphetamine-induced behavior, dopamine release, and c-fos mRNA expression: modulation by environmental novelty. Journal of Neuroscience 1998, 18:10579-10593.
16. 2 striatal neurons. Behavioural Brain Research 1999, 103:203-209.
17. Banerjee P.S., Aston J., Khundakar A.A., Zetterström T.S. Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early gene Arc in the juvenile and adult brain. European Journal of Neuroscience 2009, 29:465-476.
18. Barkley R.A., Fischer M., Smallish L., Fletcher K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003, 111:97-109.
19. Barrett S.P., Darredeau C., Bordy L.E., Pihl R.O. Characteristics of methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry 2005, 51:126-127.
20. Belin D., Everitt B.J. Drug addiction: the neural and psychological basis of a compulsive incentive habit. Handbook of Basal Ganglia Structure and Function 2010, 571-592. Elsevier, London. H. Steiner, K.Y. Tseng (Eds.).
21. Berendse H.W., Galis-de Graaf Y., Groenewegen H.J. Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. Journal of Comparative Neurology 1992, 316:314-347.
22. Berke J.D., Hyman S.E. Addiction, dopamine, and the molecular mechanisms of memory. Neuron 2000, 25:515-532.
23. Berke J.D., Paletzki R.F., Aronson G.J., Hyman S.E., Gerfen C.R. A complex program of striatal gene expression induced by dopaminergic stimulation. Journal of Neuroscience 1998, 18:5301-5310.
24. Berlanga M.L., Olsen C.M., Chen V., Ikegami A., Herring B.E., Duvauchelle C.L., Alcantara A.A. Cholinergic interneurons of the nucleus accumbens and dorsal striatum are activated by the self-administration of cocaine. Neuroscience 2003, 120:1149-1156.
25. Berman S.M., Kuczenski R., McCracken J.T., London E.D. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular Psychiatry 2009, 14:123-142.
26. Berretta S., Robertson H.A., Graybiel A.M. Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatum. Journal of Neurophysiology 1992, 68:767-777.
27. Berridge C.W., Devilbiss D.M. Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder. Biological Psychiatry 2011, 69:e101-e111.
28. Berridge C.W., Devilbiss D.M., Andrzejewski M.E., Arnsten A.F., Kelley A.E., Schmeichel B., Hamilton C., Spencer R.C. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biological Psychiatry 2006, 60:1111-1120.
29. Beveridge T.J., Smith H.R., Daunais J.B., Nader M.A., Porrino L.J. Chronic cocaine self-administration is associated with altered functional activity in the temporal lobes of non human primates. European Journal of Neuroscience 2006, 23:3109-3118.
30. Bhat R.V., Baraban J.M. Activation of transcription factor genes in striatum by cocaine: role of both serotonin and dopamine systems. Journal of Pharmacology and Experimental Therapeutics 1993, 267:496-505.
31. Bhatara V., Feil M., Hoagwood K., Vitiello B., Zima B. National trends in concomitant psychotropic medication with stimulants in pediatric visits: practice versus knowledge. Journal of Attention Disorders 2004, 7:217-226.
32. Biederman J., Wilens T.E., Spencer T.J., Adler L.A. Diagnosis and treatment of adults with attention-deficit/hyperactivity disorder. CNS Spectrums 2007, 12:1-15.
33. Black Y.D., Maclaren F.R., Naydenov A.V., Carlezon W.A.J., Baxter M.G., Konradi C. Altered attention and prefrontal cortex gene expression in rats after binge-like exposure to cocaine during adolescence. Journal of Neuroscience 2006, 26:9656-9665.
34. Bolanos C.A., Barrot M., Berton O., Wallace-Black D., Nestler E.J. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biological Psychiatry 2003, 54:1317-1329.
35. Borycz J., Zapata A., Quiroz C., Volkow N.D., Ferré S. 5-HT(1B) receptor-mediated serotoninergic modulation of methylphenidate-induced locomotor activation in rats. Neuropsychopharmacology 2008, 33:619-626.
36. Brady K.T., Gray K.M., Tolliver B.K. Cognitive enhancers in the treatment of substance use disorders: clinical evidence. Pharmacology Biochemistry and Behavior 2011, 99:285-294.
37. Brandon C.L., Marinelli M., Baker L.K., White F.J. Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology 2001, 25:651-661.
38. Brandon C.L., Steiner H. Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. European Journal of Neuroscience 2003, 18:1584-1592.
39. Breiter H.C., Gollub R.L., Weisskoff R.M., Kennedy D.N., Makris N., Berke J.D., Goodman J.M., Kantor H.L., Gastfriend D.R., Riorden J.P., Mathew R.T., Rosen B.R., Hyman S.E. Acute effects of cocaine on human brain activity and emotion. Neuron 1997, 19:591-611.
40. Brog J.S., Salyapongse A., Deutch A.Y., Zahm D.S. The patterns of afferent innervation of the core and shell in the " accumbens" part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold. Journal of Comparative Neurology 1993, 338:255-278.
41. Bronson S.E., Konradi C. Second-messenger cascades. Handbook of Basal Ganglia Structure and Function 2010, 447-460. Academic Press/Elsevier, London. H. Steiner, K.Y. Tseng (Eds.).
42. Butelman E.R., Yuferov V., Kreek M.J. κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends in Neurosciences 2012, 35:587-596.
43. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
44. Caboche J., Roze E., Brami-Cherrier K., Betuing S. Chromatin remodeling: role in neuropathologies of the basal ganglia. Handbook of Basal Ganglia Structure and Function 2010, 527-545. Academic Press/Elsevier, London. H. Steiner, K.Y. Tseng (Eds.).
45. Carey R.J., Huston J.P., Müller C.P. Pharmacological inhibition of dopamine and serotonin activity blocks spontaneous and cocaine-activated behaviour. Progress in Brain Research 2008, 172:347-360.
46. Carlezon W.A.J., Konradi C. Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology 2004, 47:47-60.
47. Carlezon W.A.J., Mague S.D., Andersen S.L. Enduring behavioral effects of early exposure to methylphenidate in rats. Biological Psychiatry 2003, 54:1330-1337.
48. Carrey N., Wilkinson M. A review of psychostimulant-induced neuroadaptation in developing animals. Neuroscience Bulletin 2011, 27:197-214.
49. Carta A.R., Gerfen C.R., Steiner H. Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice. Neuroreport 2000, 11:2395-2399.
50. Castanon N., Scearce-Levie K., Lucas J.J., Rocha B., Hen R. Modulation of the effects of cocaine by 5-HT1B receptors: a comparison of knockouts and antagonists. Pharmacology Biochemistry and Behavior 2000, 67:559-566.
51. Cenci M.A., Björklund A. Transection of corticostriatal afferents reduces amphetamine- and apomorphine-induced striatal Fos expression and turning behaviour in unilaterally 6-hydroxydopamine-lesioned rats. European Journal of Neuroscience 1993, 5:1062-1070.
52. Cenci M.A., Campbell K., Wictorin K., Björklund A. Striatal c-fos induction by cocaine or apomorphine occurs preferentially in output neurons projecting to the substantia nigra in the rat. European Journal of Neuroscience 1992, 4:376-380.
53. Chase T., Carrey N., Soo E., Wilkinson M. Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum. Neuroscience 2007, 144:969-984.
54. Chase T.D., Brown R.E., Carrey N., Wilkinson M. Daily methylphenidate administration attenuates c-fos expression in the striatum of prepubertal rats. Neuroreport 2003, 14:769-772.
55. Chase T.D., Carrey N., Brown R.E., Wilkinson M. Methylphenidate differentially regulates c-fos and fosB expression in the developing rat striatum. Developmental Brain Research 2005, 157:181-191.
56. Chase T.D., Carrey N., Brown R.E., Wilkinson M. Methylphenidate regulates c-fos and fosB expression in multiple regions of the immature rat brain. Developmental Brain Research 2005, 156:1-12.
57. Chatterjee A. Is it acceptable for people to take methylphenidate to enhance performance? No. British Medical Journal 2009, 338:b1956.
58. Chaudhuri A. Neural activity mapping with inducible transcription factors. Neuroreport 1997, 8:v-ix.
59. Chevalier G., Deniau J.M. Disinhibition as a basic process in the expression of striatal functions. Trends in Neurosciences 1990, 13:277-280.
60. 1 dopamine receptor activation of multiple transcription factor genes in rat striatum. Journal of Neurochemistry 1992, 58:1420-1426.
61. Cotterly L., Beverley J.A., Yano M., Steiner H. Dysregulation of gene induction in corticostriatal circuits after repeated methylphenidate treatment in adolescent rats: differential effects on zif 268 and homer 1a. European Journal of Neuroscience 2007, 25:3617-3628.
62. Crawford C.A., Baella S.A., Farley C.M., Herbert M.S., Horn L.R., Campbell R.H., Zavala A.R. Early methylphenidate exposure enhances cocaine self-administration but not cocaine-induced conditioned place preference in young adult rats. Psychopharmacology 2011, 213:43-52.
63. Crombag H.S., Jedynak J.P., Redmond K., Robinson T.E., Hope B.T. Locomotor sensitization to cocaine is associated with increased Fos expression in the accumbens, but not in the caudate. Behavioural Brain Research 2002, 136:455-462.
64. Csoka A., Bahrick A., Mehtonen O.P. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. Journal of Sexual Medicine 2008, 5:227-233.
65. Curran E.J., Akil H., Watson S.J. Psychomotor stimulant- and opiate-induced c-fos mRNA expression patterns in the rat forebrain: comparisons between acute drug treatment and a drug challenge in sensitized animals. Neurochemical Research 1996, 21:1425-1435.
66. Curran E.J., Watson S.J. Dopamine receptor mRNA expression patterns by opioid peptide cells in the nucleus accumbens of the rat: a double in situ hybridization study. Journal of Comparative Neurology 1995, 361:57-76.
67. Damez-Werno D., Laplant Q., Sun H., Scobie K.N., Dietz D.M., Walker I.M., Koo J.W., Vialou V.F., Mouzon E., Russo S.J., Nestler E.J. Drug experience epigenetically primes fosb gene inducibility in rat nucleus accumbens. Journal of Neuroscience 2012, 32:10267-10272.
68. Daunais J.B., McGinty J.F. Acute and chronic cocaine administration differentially alters striatal opioid and nuclear transcription factor mRNAs. Synapse 1994, 18:35-45.
69. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends in Neurosciences 1990, 13:281-285.
70. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:5274-5278.
71. Diaz Heijtz R., Kolb B., Forssberg H. Can a therapeutic dose of amphetamine during pre-adolescence modify the pattern of synaptic organization in the brain?. European Journal of Neuroscience 2003, 18:3394-3399.
72. Dilts R.P.J., Helton T.E., McGinty J.F. Selective induction of Fos and FRA immunoreactivity within the mesolimbic and mesostriatal dopamine terminal fields. Synapse 1993, 13:251-263.
73. 1 dopamine receptor-deficient mouse: cocaine-induced regulation of immediate-early gene and substance P expression in the striatum. Neuroscience 1996, 74:813-823.
74. Engber T.M., Koury E.J., Dennis S.A., Miller M.S., Contreras P.C., Bhat R.V. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neuroscience Letters 1998, 241:95-98.
75. Everitt B.J., Robbins T.W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nature Neuroscience 2005, 8:1481-1489.
76. Farah M.J., Illes J., Cook-Deegan R., Gardner H., Kandel E., King P., Parens E., Sahakian B., Wolpe P.R. Neurocognitive enhancement: what can we do and what should we do?. Nature Reviews Neuroscience 2004, 5:421-425.
77. Ferguson S.M., Eskenazi D., Ishikawa M., Wanat M.J., Phillips P.E., Dong Y., Roth B.L., Neumaier J.F. Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nature Neuroscience 2011, 14:22-24.
78. Ferguson S.M., Robinson T.E. Amphetamine-evoked gene expression in striatopallidal neurons: regulation by corticostriatal afferents and the ERK/MAPK signaling cascade. Journal of Neurochemistry 2004, 91:337-348.
79. Ferrario C.R., Gorny G., Crombag H.S., Li Y., Kolb B., Robinson T.E. Neural and behavioral plasticity associated with the transition from controlled to escalated cocaine use. Biological Psychiatry 2005, 58:751-759.
80. Filip M., Frankowska M., Zaniewska M., Gołda A., Przegaliński E. The serotonergic system and its role in cocaine addiction. Pharmacological Reports 2005, 57:685-700.
81. Fiocchi E.M., Lin Y.G., Aimone L., Gruner J.A., Flood D.G. Armodafinil promotes wakefulness and activates Fos in rat brain. Pharmacology Biochemistry and Behavior 2009, 92:549-557.
82. Fleckenstein A.E., Volz T.J., Hanson G.R. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 2009, 56(Suppl. 1):133-138.
83. Frankel P.S., Alburges M.E., Bush L., Hanson G.R., Kish S.J. Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 2008, 55:41-46.
84. Fuchs R.A., Branham R.K., See R.E. Different neural substrates mediate cocaine seeking after abstinence versus extinction training: a critical role for the dorsolateral caudate-putamen. Journal of Neuroscience 2006, 26:3584-3588.
85. Fukui R., Svenningsson P., Matsuishi T., Higashi H., Nairn A.C., Greengard P., Nishi A. Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice. Journal of Neurochemistry 2003, 87:1391-1401.
86. Gardier A.M., Moratalla R., Cuellar B., Sacerdote M., Guibert B., Lebrec H., Graybiel A.M. Interaction between the serotoninergic and dopaminergic systems in d-fenfluramine-induced activation of c-fos and jun B genes in rat striatal neurons. Journal of Neurochemistry 2000, 74:1363-1373.
87. Gatley S.J., Pan D., Chen R., Chaturvedi G., Ding Y.S. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sciences 1996, 58:231-239.
88. Gerasimov M.R., Franceschi M., Volkow N.D., Gifford A., Gatley S.J., Marsteller D., Molina P.E., Dewey S.L. Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. Journal of Pharmacology and Experimental Therapeutics 2000, 295:51-57.
89. Gerdeman G.L., Partridge J.G., Lupica C.R., Lovinger D.M. It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends in Neurosciences 2003, 26:184-192.
90. Gerfen C.R., Bolam J.P. The neuroanatomical organization of the basal ganglia. Handbook of Basal Ganglia Structure and Function 2010, 3-28. Academic Press/Elsevier, London. H. Steiner, K.Y. Tseng (Eds.).
91. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990, 250:1429-1432.
92. 1-containing neurons. Journal of Neuroscience 1995, 15:8167-8176.
93. Gill K.E., Pierre P.J., Daunais J., Bennett A.J., Martelle S., Gage H.D., Swanson J.M., Nader M.A., Porrino L.J. Chronic treatment with extended release methylphenidate does not alter dopamine systems or increase vulnerability for cocaine self-administration: a study in nonhuman primates. Neuropsychopharmacology 2012, 37:2555-2565.
94. Goldstein R.Z., Woicik P.A., Maloney T., Tomasi D., Alia-Klein N., Shan J., Honorio J., Samaras D., Wang R., Telang F., Wang G.J., Volkow N.D. Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:16667-16672.
95. Gozzi A., Colavito V., Seke Etet P.F., Montanari D., Fiorini S., Tambalo S., Bifone A., Zucconi G.G., Bentivoglio M. Modulation of fronto-cortical activity by modafinil: a functional imaging and fos study in the rat. Neuropsychopharmacology 2012, 37:822-837.
96. Graybiel A.M., Canales J.J., Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends in Neurosciences 2000, 23:S71-S77.
97. Graybiel A.M., Moratalla R., Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:6912-6916.
98. Greely H., Sahakian B., Harris J., Kessler R.C., Gazzaniga M., Campbell P., Farah M.J. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008, 456:702-705.
99. Groenewegen H.J., Berendse H.W., Wolters J.G., Lohman A.H. The anatomical relationship of the prefrontal cortex with the striatopallidal system, the thalamus and the amygdala: evidence for a parallel organization. Progress in Brain Research 1990, 85:95-116.
100. Gross N.B., Marshall J.F. Striatal dopamine and glutamate receptors modulate methamphetamine-induced cortical Fos expression. Neuroscience 2009, 161:1114-1125.
101. Gygi S.P., Gibb J.W., Hanson G.R. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. Journal of Pharmacology and Experimental Therapeutics 1994, 270:192-197.
102. Haber S.N. The primate basal ganglia: parallel and integrative networks. Journal of Chemical Neuroanatomy 2003, 26:317-330.
103. Hanson G.R., Bush L., Keefe K.A., Alburges M.E. Distinct responses of basal ganglia substance P systems to low and high doses of methamphetamine. Journal of Neurochemistry 2002, 82:1171-1178.
104. Hanson G.R., Merchant K.M., Letter A.A., Bush L., Gibb J.W. Methamphetamine-induced changes in the striatal-nigral dynorphin system: role of D-1 and D-2 receptors. European Journal of Pharmacology 1987, 144:245-246.
105. Hanson G.R., Midgley L.P., Bush L.G., Johnson M., Gibb J.W. Comparison of responses by neuropeptide systems in rat to the psychotropic drugs, methamphetamine, cocaine and PCP. NIDA Research Monograph 1989, 95:348.
106. Hanson G.R., Singh N., Merchant K., Johnson M., Bush L., Gibb J.W. Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms. Annals of the New York Academy of Sciences 1992, 668:165-172.
107. Hanson G.R., Singh N., Merchant K., Johnson M., Gibb J.W. The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse. Drug and Alcohol Dependence 1995, 37:107-110.
108. Harlan R.E., Garcia M.M. Drugs of abuse and immediate-early genes in the forebrain. Molecular Neurobiology 1998, 16:221-267.
109. Harris J. Is it acceptable for people to take methylphenidate to enhance performance? Yes. British Medical Journal 2009, 338:b1955.
110. Hasan S., Pradervand S., Ahnaou A., Drinkenburg W., Tafti M., Franken P. How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion. Neuropsychopharmacology 2009, 34:1625-1640.
111. Hawken C.M., Brown R.E., Carrey N., Wilkinson M. Long-term methylphenidate treatment down-regulates c-fos in the striatum of male CD-1 mice. Neuroreport 2004, 15:1045-1048.
112. Heiman M., Schaefer A., Gong S., Peterson J.D., Day M., Ramsey K.E., Suárez-Fariñas M., Schwarz C., Stephan D.A., Surmeier D.J., Greengard P., Heintz N. A translational profiling approach for the molecular characterization of CNS cell types. Cell 2008, 135:738-748.
113. Hope B., Kosofsky B., Hyman S.E., Nestler E.J. Regulation of immediate early gene expression and AP-1 binding in the rat nucleus accumbens by chronic cocaine. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:5764-5768.
114. Hope B.T., Nye H.E., Kelz M.B., Self D.W., Iadarola M.J., Nakabeppu Y., Duman R.S., Nestler E.J. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 1994, 13:1235-1244.
115. Hurd Y.L., Herkenham M. Influence of a single injection of cocaine, amphetamine or GBR 12909 on mRNA expression of striatal neuropeptides. Molecular Brain Research 1992, 16:97-104.
116. Hurd Y.L., Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 1993, 13:357-369.
117. Hurd Y.L., Ungerstedt U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. European Journal of Pharmacology 1989, 166:251-260.
118. Husain M., Mehta M.A. Cognitive enhancement by drugs in health and disease. Trends in Cognitive Sciences 2011, 15:28-36.
119. Hyman S.E. Addiction: a disease of learning and memory. American Journal of Psychiatry 2005, 162:1414-1422.
120. Hyman S.E. Cognitive enhancement: promises and perils. Neuron 2011, 69:595-598.
121. Hyman S.E., Cole R.L., Schwarzschild M., Cole D., Hope B., Konradi C. Molecular mechanisms of striatal gene regulation: a critical role for glutamate in dopamine-mediated gene induction. Pharmacological Regulation of Gene Expression in the CNS 1996, 115-131. CRC, Boca Raton. K.M. Merchant (Ed.).
122. Hyman S.E., Malenka R.C. Addiction and the brain: the neurobiology of compulsion and its persistence. Nature Reviews Neuroscience 2001, 2:695-703.
123. Hyman S.E., Nestler E.J. Initiation and adaptation: a paradigm for understanding psychotropic drug action. American Journal of Psychiatry 1996, 153:151-162.
124. Ishii M., Tatsuzawa Y., Yoshino A., Nomura S. Serotonin syndrome induced by augmentation of SSRI with methylphenidate. Psychiatry and Clinical Neurosciences 2008, 62:246.
125. Jaber M., Cador M., Dumartin B., Normand E., Stinus L., Bloch B. Acute and chronic amphetamine treatments differently regulate neuropeptide messenger RNA levels and Fos immunoreactivity in rat striatal neurons. Neuroscience 1995, 65:1041-1050.
126. Jedynak J.P., Uslaner J.M., Esteban J.A., Robinson T.E. Methamphetamine-induced structural plasticity in the dorsal striatum. European Journal of Neuroscience 2007, 25:847-853.
127. Joel D., Weiner I. The organization of the basal ganglia-thalamocortical circuits: open interconnected rather than closed segregated. Neuroscience 1994, 63:363-379.
128. Johansson B., Lindström K., Fredholm B.B. Differences in the regional and cellular localization of c-fos messenger RNA induced by amphetamine, cocaine and caffeine in the rat. Neuroscience 1994, 59:837-849.
129. Johnson M., Bush L.G., Gibb J.W., Hanson G.R. Role of N-methyl-d-aspartate (NMDA) receptors in the response of extrapyramidal neurotensin and dynorphin A systems to cocaine and GBR 12909. Biochemical Pharmacology 1991, 41:649-652.
130. Kankaanpaa A., Meririnne E., Seppala T. 5-HT3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat. Psychopharmacology 2002, 159:341-350.
131. Keefe K.A., Horner K.A. Neurotransmitter regulation of basal ganglia gene expression. Handbook of Basal Ganglia Structure and Function 2010, 461-490. Academic Press/Elsevier, London. H. Steiner, K.Y. Tseng (Eds.).
132. Kelley A.E. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 2004, 44:161-179.
133. Kim Y., Teylan M.A., Baron M., Sands A., Nairn A.C., Greengard P. Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:2915-2920.
134. Knapska E., Kaczmarek L. A gene for neuronal plasticity in the mammalian brain: Zif268/Egr-1/NGFI-A/Krox-24/TIS8/ZENK?. Progress in Neurobiology 2004, 74:183-211.
135. Kollins S.H. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. Journal of Attention Disorders 2008, 12:115-125.
136. Kollins S.H., MacDonald E.K., Rush C.R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacology Biochemistry and Behavior 2001, 68:611-627.
137. Konradi C., Westin J.E., Carta M., Eaton M.E., Kuter K., Dekundy A., Lundblad M., Cenci M.A. Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia. Neurobiology of Disease 2004, 17:219-236.
138. Kosofsky B.E., Genova L.M., Hyman S.E. Substance P phenotype defines specificity of c-fos induction by cocaine in developing rat striatum. Journal of Comparative Neurology 1995, 351:41-50.
139. Kravitz A.V., Freeze B.S., Parker P.R., Kay K., Thwin M.T., Deisseroth K., Kreitzer A.C. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010, 466:622-626.
140. Kuczenski R., Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. Journal of Neurochemistry 1997, 68:2032-2037.
141. Kuczenski R., Segal D.S. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. Journal of Pharmacology and Experimental Therapeutics 2001, 296:876-883.
142. Kuczenski R., Segal D.S. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biological Psychiatry 2005, 57:1391-1396.
143. Kuhar M.J., Pilotte N.S. Neurochemical changes in cocaine withdrawal. Trends in Pharmacological Sciences 1996, 17:260-264.
144. 2 synergism and its breakdown. Brain Research 1996, 728:97-104.
145. 2 synergism and receptor supersensitivity. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:7451-7455.
146. Lanni C., Lenzken S.C., Pascale A., Del Vecchio I., Racchi M., Pistoia F., Govoni S. Cognition enhancers between treating and doping the mind. Pharmacological Research 2008, 57:196-213.
147. Lavretsky H., Kim M.D., Kumar A., Reynolds C.F. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. Journal of Clinical Psychiatry 2003, 64:1410-1414.
148. 2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. Journal of Comparative Neurology 1995, 355:418-426.
149. 2 dopamine receptors. Neuroscience 1996, 73:131-143.
150. 1 dopamine receptor gene. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:4205-4209.
151. Le Moine C., Normand E., Guitteny A.F., Fouque B., Teoule R., Bloch B. Dopamine receptor gene expression by enkephalin neurons in rat forebrain. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:230-234.
152. 1 receptor-mediated effects on c-fos expression. Journal of Neuroscience 1997, 17:8038-8048.
153. Leonard B.E., McCartan D., White J., King D.J. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Human Psychopharmacology 2004, 19:151-180.
154. Letter A.A., Merchant K., Gibb J.W., Hanson G.R. Effect of methamphetamine on neurotensin concentrations in rat brain regions. Journal of Pharmacology and Experimental Therapeutics 1987, 241:443-447.
155. Li B.H., Rowland N.E. Dexfenfluramine induces Fos-like immunoreactivity in discrete brain regions in rats. Brain Research Bulletin 1993, 31:43-48.
156. Li S.J., Sivam S.P., McGinty J.F., Jiang H.K., Douglass J., Calavetta L., Hong J.S. Regulation of the metabolism of striatal dynorphin by the dopaminergic system. Journal of Pharmacology and Experimental Therapeutics 1988, 246:403-408.
157. Lin J.S., Hou Y., Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:14128-14133.
158. Lobo M.K., Covington H.E., Chaudhury D., Friedman A.K., Sun H., Damez-Werno D., Dietz D.M., Zaman S., Koo J.W., Kennedy P.J., Mouzon E., Mogri M., Neve R.L., Deisseroth K., Han M.H., Nestler E.J. Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science 2010, 330:385-390.
159. Lobo M.K., Nestler E.J. The striatal balancing act in drug addiction: distinct roles of direct and indirect pathway medium spiny neurons. Frontiers in Neuroanatomy 2011, 5:41.
160. Loland C.J., Mereu M., Okunola O.M., Cao J., Prisinzano T.E., Mazier S., Kopajtic T., Shi L., Katz J.L., Tanda G., Newman A.H. R-Modafinil (Armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biological Psychiatry 2012, 72:405-413.
161. London E.D., Cascella N.G., Wong D.F., Phillips R.L., Dannals R.F., Links J.M., Herning R., Grayson R., Jaffe J.H., Wagner H.N.J. Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [fluorine 18]-fluorodeoxyglucose. Archives of General Psychiatry 1990, 47:567-574.
162. Lucas J.J., Segu L., Hen R. 5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. Molecular Pharmacology 1997, 51:755-763.
163. Mache S., Eickenhorst P., Vitzthum K., Klapp B.F., Groneberg D.A. Cognitive-enhancing substance use at German universities: frequency, reasons and gender differences. Wiener Medizinische Wochenschrift 2012, 162:262-271.
164. Madras B.K., Xie Z., Lin Z., Jassen A., Panas H., Lynch L., Johnson R., Livni E., Spencer T.J., Bonab A.A., Miller G.M., Fischman A.J. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. Journal of Pharmacology and Experimental Therapeutics 2006, 319:561-569.
165. Maher B. Poll results: look who's doping. Nature 2008, 452:674-675.
166. Marco E.M., Adriani W., Ruocco L.A., Canese R., Sadile A.G., Laviola G. Neurobehavioral adaptations to methylphenidate: the issue of early adolescent exposure. Neuroscience and Biobehavioral Reviews 2011, 35:1722-1739.
167. Mathieu-Kia A.M., Besson M.J. Repeated administration of cocaine, nicotine and ethanol: effects on preprodynorphin, preprotachykinin A and preproenkephalin mRNA expression in the dorsal and the ventral striatum of the rat. Molecular Brain Research 1998, 54:141-151.
168. Mattson B.J., Koya E., Simmons D.E., Mitchell T.B., Berkow A., Crombag H.S., Hope B.T. Context-specific sensitization of cocaine-induced locomotor activity and associated neuronal ensembles in rat nucleus accumbens. European Journal of Neuroscience 2008, 27:202-212.
169. McClung C.A., Nestler E.J. Regulation of gene expression and cocaine reward by CREB and DeltaFosB. Nature Neuroscience 2003, 6:1208-1215.
170. McClung C.A., Ulery P.G., Perrotti L.I., Zachariou V., Berton O., Nestler E.J. DeltaFosB: a molecular switch for long-term adaptation in the brain. Molecular Brain Research 2004, 132:146-154.
171. McGeorge A.J., Faull R.L.M. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 1989, 29:503-537.
172. McGinty J.F., Shi X.D., Schwendt M., Saylor A., Toda S. Regulation of psychostimulant-induced signaling and gene expression in the striatum. Journal of Neurochemistry 2008, 104:1440-1449.
173. 2-receptor antagonists. Journal of Pharmacology and Experimental Therapeutics 2001, 298:539-550.
174. Mijnster M.J., Galis-de Graaf Y., Voorn P. Serotonergic regulation of neuropeptide and glutamic acid decarboxylase mRNA levels in the rat striatum and globus pallidus: studies with fluoxetine and DOI. Molecular Brain Research 1998, 54:64-73.
175. Minzenberg M.J., Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33:1477-1502.
176. Moratalla R., Elibol B., Vallejo M., Graybiel A.M. Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal. Neuron 1996, 17:147-156.
177. Moratalla R., Robertson H.A., Graybiel A.M. Dynamic regulation of NGFI-A (zif268, egr1) gene expression in the striatum. Journal of Neuroscience 1992, 12:2609-2622.
178. 1 dopamine receptor. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:14928-14933.
179. Morris B.J., Reimer S., Hollt V., Herz A. Regulation of striatal prodynorphin mRNA levels by the raphe-striatal pathway. Brain Research 1988, 464:15-22.
180. Muller C.P., Huston J.P. Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine. Trends in Pharmacological Sciences 2006, 27:105-112.
181. Nakabeppu Y., Nathans D. A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell 1991, 64:751-759.
182. Naqvi N.H., Rudrauf D., Damasio H., Bechara A. Damage to the insula disrupts addiction to cigarette smoking. Science 2007, 315:531-534.
183. Natarajan R., Yamamoto B.K. The basal ganglia as a substrate for the multiple actions of amphetamines. Basal Ganglia 2011, 1:49-57.
184. Nelson J.C. Augmentation strategies in the treatment of major depressive disorder. Recent findings and current status of augmentation strategies. CNS Spectrums 2007, 12(Suppl. 22):6-9.
185. Nestler E.J. Molecular basis of long-term plasticity underlying addiction. Nature Reviews Neuroscience 2001, 2:119-128.
186. Nestler E.J., Carlezon W.A.J. The mesolimbic dopamine reward circuit in depression. Biological Psychiatry 2006, 59:1151-1159.
187. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-Fos and Zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:4270-4274.
188. Nye H.E., Hope B.T., Kelz M.B., Iadarola M., Nestler E.J. Pharmacological studies of the regulation of chronic FOS-related antigen induction by cocaine in the striatum and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 1995, 275:1671-1680.
189. O'Connor E.C., Chapman K., Butler P., Mead A.N. The predictive validity of the rat self-administration model for abuse liability. Neuroscience and Biobehavioral Reviews 2011, 35:912-938.
190. Oberlander T.F., Gingrich J.A., Ansorge M.S. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clinical Pharmacology and Therapeutics 2009, 86:672-677.
191. Olivier J.D., Blom T., Arentsen T., Homberg J.R. The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review. Progress in Neuropsychopharmacology and Biological Psychiatry 2011, 35:1400-1408.
192. Oorschot D.E. Cell types in the different nuclei of the basal ganglia. Handbook of Basal Ganglia Structure and Function 2010, 63-74. Academic Press/Elsevier, London. H. Steiner, K.Y. Tseng (Eds.).
193. Oorschot, D.E. The percentage of interneurons in the dorsal striatum of the rat, cat, monkey and human: a critique of the evidence. Basal Ganglia 3, in press.
194. Outram S.M. The use of methylphenidate among students: the future of enhancement?. Journal of Medical Ethics 2010, 36:198-202.
195. Pan D., Gatley S.J., Dewey S.L., Chen R., Alexoff D.A., Ding Y.S., Fowler J.S. Binding of bromine-substituted analogs of methylphenidate to monoamine transporters. European Journal of Neuroscience 1994, 264:177-182.
196. Parran T.V.J., Jasinski D.R. Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Archives of Internal Medicine 1991, 151:781-783.
197. Pascoli V., Valjent E., Corbille A.G., Corvol J.C., Tassin J.P., Girault J.A., Herve D. cAMP and extracellular signal-regulated kinase signaling in response to d-amphetamine and methylphenidate in the prefrontal cortex in vivo: role of beta1-adrenoceptors. Molecular Pharmacology 2005, 68:421-429.
198. Passingham R.E., Myers C., Rawlins N., Lightfoot V., Fearn S. Premotor cortex in the rat. Behavioral Neuroscience 1988, 102:101-109.
199. 2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. Journal of Neuroscience 1992, 12:3729-3742.
200. Penner M.R., McFadyen M.P., Pinaud R., Carrey N., Robertson H.A., Brown R.E. Age-related distribution of c-fos expression in the striatum of CD-1 mice after acute methylphenidate administration. Developmental Brain Research 2002, 135:71-77.
201. Persico A.M., Schindler C.W., Brannock M.T., Gonzalez A.M., Surratt C.K., Uhl G.R. Dopaminergic gene expression during amphetamine withdrawal. Neuroreport 1993, 4:41-44.
202. Petersen T., Dording C., Neault N.B., Kornbluh R., Alpert J.E., Nierenberg A.A., Rosenbaum J.F., Fava M. A survey of prescribing practices in the treatment of depression. Progress in Neuropsychopharmacology and Biological Psychiatry 2002, 26:177-187.
203. Pierce R.C., Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Research Reviews 1997, 25:192-216.
204. Pinna A., Wardas J., Cristalli G., Morelli M. Adenosine A2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas. Brain Research 1997, 759:41-49.
205. Pisani A., Bernardi G., Ding J., Surmeier D.J. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends in Neurosciences 2007, 30:545-553.
206. Porrino L.J., Smith H.R., Nader M.A., Beveridge T.J. The effects of cocaine: a shifting target over the course of addiction. Progress in Neuropsychopharmacology and Biological Psychiatry 2007, 31:1593-1600.
207. Preuss T.M. Do rats have prefrontal cortex? The Rose-Woolsey-Akert program reconsidered. Journal of Cognitive Neuroscience 1995, 7:1-24.
208. 2 receptors are essential for the arousal effect of modafinil. Journal of Neuroscience 2008, 28:8462-8469.
209. Ravindran A.V., Kennedy S.H., O'Donovan M.C., Fallu A., Camacho F., Binder C.E. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. Journal of Clinical Psychiatry 2008, 69:87-94.
210. Redgrave P., Rodriguez M., Smith Y., Rodriguez-Oroz M.C., Lehericy S., Bergman H., Agid Y., DeLong M.R., Obeso J.A. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nature Reviews Neuroscience 2010, 11:760-772.
211. Reep R.L., Cheatwood J.L., Corwin J.V. The associative striatum: organization of cortical projections to the dorsocentral striatum in rats. Journal of Comparative Neurology 2003, 467:271-292.
212. Reep R.L., Corwin J.V., Hashimoto A., Watson R.T. Efferent connections of the rostral portion of medial agranular cortex in rats. Brain Research Bulletin 1987, 19:203-221.
213. Reichel C.M., See R.E. Chronic modafinil effects on drug-seeking following methamphetamine self-administration in rats. International Journal of Neuropsychopharmacology 2012, 15:919-929.
214. Renthal W., Carle T.L., Maze I., Covington H.E.r., Truong H.T., Alibhai I., Kumar A., Montgomery R.L., Olson E.N., Nestler E.J. Delta FosB mediates epigenetic desensitization of the c-fos gene after chronic amphetamine exposure. Journal of Neuroscience 2008, 28:7344-7349.
215. Renthal W., Nestler E.J. Epigenetic mechanisms in drug addiction. Trends in Molecular Medicine 2008, 14:341-350.
216. Ritz M.C., Cone E.J., Kuhar M.J. Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sciences 1990, 46:635-645.
217. Robbins T.W., Everitt B.J. Drug addiction: bad habits add up. Nature 1999, 398:567-570.
218. Robbins T.W., Granon S., Muir J.L., Durantou F., Harrison A., Everitt B.J. Neural systems underlying arousal and attention. Implications for drug abuse. Annals of the New York Academy of Sciences 1998, 846:222-237.
219. Robinson T.E., Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. Journal of Neuroscience 1997, 17:8491-8497.
220. 2 dopamine receptor activation. Synapse 1994, 18:233-240.
221. Safer D.J., Zito J.M., DosReis S. Concomitant psychotropic medication for youths. American Journal of Psychiatry 2003, 160:438-449.
222. Samaha A.N., Mallet N., Ferguson S.M., Gonon F., Robinson T.E. The rate of cocaine administration alters gene regulation and behavioral plasticity: implications for addiction. Journal of Neuroscience 2004, 24:6362-6370.
223. Samaha A.N., Robinson T.E. Why does the rapid delivery of drugs to the brain promote addiction?. Trends in Pharmacological Sciences 2005, 26:82-87.
224. Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. Journal of Neuroscience 2002, 22:8705-8710.
225. Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. Journal of Pharmacology and Experimental Therapeutics 2003, 304:1181-1187.
226. Sato S.M., Wissman A.M., McCollum A.F., Woolley C.S. Quantitative mapping of cocaine-induced ΔFosB expression in the striatum of male and female rats. PLoS One 2011, 6:e21783.
227. Scammell T.E., Estabrooke I.V., McCarthy M.T., Chemelli R.M., Yanagisawa M., Miller M.S., Saper C.B. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. Journal of Neuroscience 2000, 20:8620-8628.
228. Schenk S., Izenwasser S. Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine. Pharmacology Biochemistry and Behavior 2002, 72:651-657.
229. Schmitt K.C., Reith M.E. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS One 2011, 6:e25790.
230. 3 receptor coexistence. Brain Research Reviews 1998, 26:236-242.
231. Schweri M.M., Skolnick P., Rafferty M.F., Rice K.C., Janowsky A.J., Paul S.M. [3H]Threo-(±)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. Journal of Neurochemistry 1985, 45:1062-1070.
232. See R.E., Elliott J.C., Feltenstein M.W. The role of dorsal vs ventral striatal pathways in cocaine-seeking behavior after prolonged abstinence in rats. Psychopharmacology 2007, 194:321-331.
233. Segal D.S., Kuczenski R. Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile. Journal of Pharmacology and Experimental Therapeutics 1999, 291:19-30.
234. Sharp F.R., Sagar S.M., Swanson R.A. Metabolic mapping with cellular resolution: c-fos vs. 2-deoxyglucose. Critical Reviews in Neurobiology 1993, 7:205-228.
235. Shippenberg T.S., Heidbreder C. Sensitization to the conditioned rewarding effects of cocaine: pharmacological and temporal characteristics. Journal of Pharmacology and Experimental Therapeutics 1995, 273:808-815.
236. Shippenberg T.S., Zapata A., Chefer V.I. Dynorphin and the pathophysiology of drug addiction. Pharmacology and Therapeutics 2007, 116:306-321.
237. Sivam S.P. Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism. Journal of Pharmacology and Experimental Therapeutics 1989, 250:818-824.
238. Smiley P.L., Johnson M., Bush L., Gibb J.W., Hanson G.R. Effects of cocaine on extrapyramidal and limbic dynorphin systems. Journal of Pharmacology and Experimental Therapeutics 1990, 253:938-943.
239. Smith A.J.W., McGinty J.F. Acute amphetamine or methamphetamine alters opioid peptide mRNA expression in rat striatum. Molecular Brain Research 1994, 21:359-362.
240. Sofuoglu M., Devito E.E., Waters A.J., Carroll K.M. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology 2013, 64:452-463.
241. Solanto M.V. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behavioural Brain Research 2002, 130:65-71.
242. Spangler R., Unterwald E.M., Kreek M.J. 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Molecular Brain Research 1993, 19:323-327.
243. Spangler R., Zhou Y., Maggos C.E., Schlussman S.D., Ho A., Kreek M.J. Prodynorphin, proenkephalin and kappa opioid receptor mRNA responses to acute " binge" cocaine. Molecular Brain Research 1997, 44:139-142.
244. 1 dopamine receptors in the striatum. Monoaminergic Modulation of Cortical Excitability 2007, 265-285. Springer, Berlin. K.Y. Tseng, M. Atzori (Eds.).
245. Steiner H. Psychostimulant-induced gene regulation in corticostriatal circuits. Handbook of Basal Ganglia Structure and Function 2010, 501-525. Academic Press/Elsevier, London. H. Steiner, K.Y. Tseng (Eds.).
246. Steiner H., Gerfen C.R. Cocaine-induced c-fos messenger RNA is inversely related to dynorphin expression in striatum. Journal of Neuroscience 1993, 13:5066-5081.
247. Steiner H., Gerfen C.R. Tactile sensory input regulates basal and apomorphine-induced immediate-early gene expression in rat barrel cortex. Journal of Comparative Neurology 1994, 344:297-304.
248. 1 dopamine receptor-mediated immediate-early gene expression in the striatum. Journal of Comparative Neurology 1995, 353:200-212.
249. 1 dopamine receptor-mediated responses in the striatum: relative contributions of pre- and postsynaptic mechanisms in dorsal and ventral striatum demonstrated by altered immediate-early gene induction. Journal of Comparative Neurology 1996, 376:530-541.
250. Steiner H., Gerfen C.R. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Experimental Brain Research 1998, 123:60-76.
251. 2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons. Neuroscience 1999, 88:795-810.
252. 1 dopamine receptors in the striatum. Journal of Neuroscience 2000, 20:5449-5460.
253. Steiner H., Van Waes V., Marinelli M. Fluoxetine potentiates methylphenidate-induced gene regulation in addiction-related brain regions: concerns for use of cognitive enhancers?. Biological Psychiatry 2010, 67:592-594.
254. Sulzer D. How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 2011, 69:628-649.
255. Svetlov S.I., Kobeissy F.H., Gold M.S. Performance enhancing, non-prescription use of Ritalin: a comparison with amphetamines and cocaine. Journal of Addictive Diseases 2007, 26:1-6.
256. Swanson J.M., Volkow N.D. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neuroscience and Biobehavioral Reviews 2003, 27:615-621.
257. Swanson J.M., Volkow N.D. Increasing use of stimulants warns of potential abuse. Nature 2008, 453:586.
258. Teter C.J., McCabe S.E., LaGrange K., Cranford J.A., Boyd C.J. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006, 26:1501-1510.
259. Thanos P.K., Michaelides M., Benveniste H., Wang G.J., Volkow N.D. Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. Pharmacology Biochemistry and Behavior 2007, 87:426-433.
260. Thomas U. Modulation of synaptic signalling complexes by Homer proteins. Journal of Neurochemistry 2002, 81:407-413.
261. Todtenkopf M.S., Mihalakopoulos A., Stellar J.R. Withdrawal duration differentially affects c-fos expression in the medial prefrontal cortex and discrete subregions of the nucleus accumbens in cocaine-sensitized rats. Neuroscience 2002, 114:1061-1069.
262. Torres G., Horowitz J.M. Drugs of abuse and brain gene expression. Psychosomatic Medicine 1999, 61:630-650.
263. Torres G., Rivier C. Cocaine-induced expression of striatal c-fos in the rat is inhibited by NMDA receptor antagonists. Brain Research Bulletin 1993, 30:173-176.
264. Torres G., Rivier C. Induction of c-fos in rat brain by acute cocaine and fenfluramine exposure: a comparison study. Brain Research 1994, 647:1-9.
265. Touret M., Sallanon-Moulin M., Fages C., Roudier V., Didier-Bazes M., Roussel B., Tardy M., Jouvet M. Effects of modafinil-induced wakefulness on glutamine synthetase regulation in the rat brain. Molecular Brain Research 1994, 26:123-128.
266. Trinh J.V., Nehrenberg D.L., Jacobsen J.P., Caron M.G., Wetsel W.C. Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice. Neuroscience 2003, 118:297-310.
267. Tropea T.F., Guerriero R.M., Willuhn I., Unterwald E.M., Ehrlich M.E., Steiner H., Kosofsky B.E. Augmented D1 dopamine receptor signaling and immediate-early gene induction in adult striatum after prenatal cocaine. Biological Psychiatry 2008, 63:1066-1074.
268. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addiction Biology 2007, 12:227-462.
269. Unal C.T., Beverley J.A., Willuhn I., Steiner H. Long-lasting dysregulation of gene expression in corticostriatal circuits after repeated cocaine treatment in adult rats: effects on zif 268 and homer 1a. European Journal of Neuroscience 2009, 29:1615-1626.
270. Uslaner J., Badiani A., Norton C.S., Day H.E., Watson S.J., Akil H., Robinson T.E. Amphetamine and cocaine induce different patterns of c-fos mRNA expression in the striatum and subthalamic nucleus depending on environmental context. European Journal of Neuroscience 2001, 13:1977-1983.
271. Uylings H.B., Groenewegen H.J., Kolb B. Do rats have a prefrontal cortex?. Behavioural Brain Research 2003, 146:3-17.
272. Van Waes V., Beverley J., Marinelli M., Steiner H. Selective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum. European Journal of Neuroscience 2010, 32:435-447.
273. Van Waes V., Carr B., Beverley J.A., Steiner H. Fluoxetine potentiation of methylphenidate-induced neuropeptide expression in the striatum occurs selectively in direct pathway (striatonigral) neurons. Journal of Neurochemistry 2012, 122:1054-1064.
274. Van Waes V., Vandrevala M., Beverley J., Steiner H. SSRIs potentiate methylphenidate-induced blunting of gene expression in the adolescent striatum. Society for Neuroscience Abstracts 2012, 42. 778.15.
275. Vanderschuren L.J., Di Ciano P., Everitt B.J. Involvement of the dorsal striatum in cue-controlled cocaine seeking. Journal of Neuroscience 2005, 25:8665-8670.
276. Vanderschuren L.J., Everitt B.J. Behavioral and neural mechanisms of compulsive drug seeking. European Journal of Pharmacology 2005, 526:77-88.
277. Vargo J.M., Marshall J.F. Time-dependent changes in dopamine agonist-induced striatal Fos immunoreactivity are related to sensory neglect and its recovery after unilateral prefrontal cortex injury. Synapse 1995, 20:305-315.
278. Vezina P. Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neuroscience and Biobehavioral Reviews 2004, 27:827-839.
279. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., Wang G.J., Jayne M., Hooker J.M., Wong C., Hubbard B., Carter P., Warner D., King P., Shea C., Xu Y., Muench L., Apelskog-Torres K. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. Journal of the American Medical Association 2009, 301:1148-1154.
280. Volkow N.D., Wang G., Fowler J.S., Logan J., Gerasimov M., Maynard L., Ding Y., Gatley S.J., Gifford A., Franceschi D. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. Journal of Neuroscience 2001, 21(RC121):1-5.
281. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry 1998, 155:1325-1331.
282. Volkow N.D., Wang G.J., Tomasi D., Telang F., Fowler J.S., Pradhan K., Jayne M., Logan J., Goldstein R.Z., Alia-Klein N., Wong C. Methylphenidate attenuates limbic brain inhibition after cocaine-cues exposure in cocaine abusers. PLoS One 2010, 5:e11509.
283. Wakabayashi K.T., Weiss M.J., Pickup K.N., Robinson T.E. Rats markedly escalate their intake and show a persistent susceptibility to reinstatement only when cocaine is injected rapidly. Journal of Neuroscience 2010, 30:11346-11355.
284. Walker P.D., Capodilupo J.G., Wolf W.A., Carlock L.R. Preprotachykinin and preproenkephalin mRNA expression within striatal subregions in response to altered serotonin transmission. Brain Research 1996, 732:25-35.
285. Wall S.C., Gu H., Rudnick G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Molecular Pharmacology 1995, 47:544-550.
286. Wang J.Q., Daunais J.B., McGinty J.F. NMDA receptors mediate amphetamine-induced upregulation of zif/268 and preprodynorphin mRNA expression in rat striatum. Synapse 1994, 18:343-353.
287. Wang J.Q., Daunais J.B., McGinty J.F. Role of kainate/AMPA receptors in induction of striatal zif/268 and preprodynorphin mRNA by a single injection of amphetamine. Molecular Brain Research 1994, 27:118-126.
288. Wang J.Q., McGinty J.F. Alterations in striatal zif/268, preprodynorphin and preproenkephalin mRNA expression induced by repeated amphetamine administration in rats. Brain Research 1995, 673:262-274.
289. Wang J.Q., McGinty J.F. Dose-dependent alteration in zif/268 and preprodynorphin mRNA expression induced by amphetamine or methamphetamine in rat forebrain. Journal of Pharmacology and Experimental Therapeutics 1995, 273:909-917.
290. 2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine. Synapse 1996, 22:114-122.
291. Wang J.Q., McGinty J.F. Glutamatergic and cholinergic regulation of immediate-early gene and neuropeptide gene expression in the striatum. Pharmacological Regulation of Gene Expression in the CNS 1996, 81-113. CRC, Boca Raton. K.M. Merchant (Ed.).
292. 2 interactions by muscarinic receptors. Journal of Pharmacology and Experimental Therapeutics 1997, 281:972-982.
293. Wang J.Q., Smith A.J.W., McGinty J.F. A single injection of amphetamine or methamphetamine induces dynamic alterations in c-fos, zif/268 and preprodynorphin messenger RNA expression in rat forebrain. Neuroscience 1995, 68:83-95.
294. Warren B.L., Iñiguez S.D., Alcantara L.F., Wright K.N., Parise E.M., Weakley S.K., Bolaños-Guzmán C.A. Juvenile administration of concomitant methylphenidate and fluoxetine alters behavioral reactivity to reward- and mood-related stimuli and disrupts ventral tegmental area gene expression in adulthood. Journal of Neuroscience 2011, 31:10347-10358.
295. White B.P., Becker-Blease K.A., Grace-Bishop K. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. Journal of American College Health 2006, 54:261-268.
296. Wilens T.E., Adler L.A., Adams J., Sgambati S., Rotrosen J., Sawtelle R., Utzinger L., Fusillo S. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry 2008, 47:21-31.
297. Wilens T.E., Faraone S.V., Biederman J., Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003, 111:179-185.
298. Wiley M.D., Poveromo L.B., Antapasis J., Herrera C.M., Bolaños Guzmán C.A. Kappa-opioid system regulates the long-lasting behavioral adaptations induced by early-life exposure to methylphenidate. Neuropsychopharmacology 2009, 34:1339-1350.
299. Willie J.T., Renthal W., Chemelli R.M., Miller M.S., Scammell T.E., Yanagisawa M., Sinton C.M. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience 2005, 130:983-995.
300. Willuhn I., Sun W., Steiner H. Topography of cocaine-induced gene regulation in the rat striatum: relationship to cortical inputs and role of behavioural context. European Journal of Neuroscience 2003, 17:1053-1066.
301. Wirtshafter D., Cook D.F. Serotonin-1B agonists induce compartmentally organized striatal Fos expression in rats. Neuroreport 1998, 9:1217-1221.
302. Wright C.I., Groenewegen H.J. Patterns of overlap and segregation between insular cortical, intermediodorsal thalamic and basal amygdaloid afferents in the nucleus accumbens of the rat. Neuroscience 1996, 73:359-373.
303. Xiao B., Tu J.C., Worley P.F. Homer: a link between neural activity and glutamate receptor function. Current Opinion in Neurobiology 2000, 10:370-374.
304. 1 dopamine receptors: interhemispheric effects. Neuroscience 2006, 140:699-709.
305. Yano M., Steiner H. Methylphenidate (Ritalin) induces Homer 1a and zif 268 expression in specific corticostriatal circuits. Neuroscience 2005, 132:855-865.
306. Yano M., Steiner H. Topography of methylphenidate (Ritalin)-induced gene regulation in the striatum: differential effects on c-fos, substance P and opioid peptides. Neuropsychopharmacology 2005, 30:901-915.
307. Yano M., Steiner H. Methylphenidate and cocaine: the same effects on gene regulation?. Trends in Pharmacological Sciences 2007, 28:588-596.
308. Yoo J.H., Kitchen I., Bailey A. The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?. British Journal of Pharmacology 2012, 166:1993-2014.
309. 1 receptors?. Biological Psychiatry 2010, 67:784-787.
310. 1 receptors. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:1291-1295.
311. Yuferov V., Nielsen D., Butelman E., Kreek M.J. Microarray studies of psychostimulant-induced changes in gene expression. Addiction Biology 2005, 10:101-118.
312. 3 receptors. Journal of Neuroscience 2004, 24:3344-3354.
313. Zhu J., Spencer T.J., Liu-Chen L.Y., Biederman J., Bhide P.G. Methylphenidate and μ opioid receptor interactions: a pharmacological target for prevention of stimulant abuse. Neuropharmacology 2011, 61:283-292.